Journal of Clinical Oncology - ASCO Publications
WEBOct 2, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a …
Management of Immune-Related Adverse Events in Patients …
WEBImmunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize and attack cancer ...
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
WEBDec 22, 2021 · An estimated 105,000 new cases of colon cancer were diagnosed in the United States in 2021, 1 of which approximately 39% were localized. 2 Stage II cancers are characterized by a lack of metastatic spread or lymph node involvement, and the main treatment is surgical resection of the primary tumor. Prognosis after resection is relatively favorable, with an estimated 5-year disease-free survival ...
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Management of Immune-Related Adverse Events in Patients …
WEBNov 1, 2021 · The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most common CAR T-cell–related toxicities, including cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, B-cell aplasia, cytopenias, and infections.
Management of Cancer Therapy–Associated Oral Mucositis
WEBFeb 3, 2020 · Abstract. Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis …
Global Radiotherapy: Current Status and Future Directions—White …
WEBJun 8, 2021 · The WHO states that the highest attainable standard of health is a fundamental right of every human being. 1 Factors such as availability, accessibility, acceptability, and quality are fundamental to obtain the highest attainable standard of health. 2 Although there is mounting evidence that good health care can benefit the gross domestic product, radiotherapy is still seen as an expense ...
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: …
WEBJun 20, 2022 · Total neoadjuvant therapy (TNT) is now recognized as the preferred standard for the treatment of locally advanced rectal cancer. 1 Using this approach, all nonsurgical interventions, including multiagent chemotherapy and concurrent chemoradiotherapy (CRT), are administered before surgical resection or the decision on nonoperative management is made. . Multiagent systemic chemotherapy regimens ...
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions …
WEBFeb 1, 2021 · For phase I trials of novel anticancer treatments, many of the assumptions of traditional dose-finding designs are no longer valid. Commonly, current dose-finding designs involve escalation of more than one agent, identification of an optimal biologic dose or minimum effective dose (MED), on the basis of safety and efficacy, and late-onset toxicities.
Updated Diagnostic Criteria and Staging System for Multiple …
WEBMay 19, 2016 · The diagnosis of MM requires 10% or more clonal plasma cells on bone marrow examination or a biopsy-proven plasmacytoma plus the presence of one or more myeloma-defining events. 10 Myeloma-defining events include the presence of one or more CRAB features, or one or more biomarkers of malignancy. The three biomarkers included in the definition of MM are associated with an approximately 80% risk ...